Journal
Annals of Oncology
Publication Date
9-1-2020
Volume
31
Issue
9
First Page
1223
Last Page
1230
Document Type
Open Access Publication
DOI
10.1016/j.annonc.2020.05.012
Rights and Permissions
Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A; CONTROL Study Investigators. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020 Sep;31(9):1223-1230. doi: 10.1016/j.annonc.2020.05.012. © 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Recommended Citation
Barcenas, C H; Bose, R; and et al., "Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: The CONTROL trial." Annals of Oncology. 31, 9. 1223 - 1230. (2020).
https://digitalcommons.wustl.edu/oa_4/1328
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
